A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease

Prins, ND; Harrison, JE; Chu, HM; Blackburn, K; Alam, JJ; Scheltens, P

Prins, ND (corresponding author), Amsterdam UMC, Dept Neurol, Alzheimer Ctr, Amsterdam, Netherlands.; Prins, ND (corresponding author), Brain Res Ctr, Amsterdam, Netherlands.

ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1):

Abstract

Background: In preclinical studies, p38a; kinase is implicated in Alzheimer's disease (AD) pathogenesis. In animal models, it mediates impaired synapt......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索